Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
| Autor: | Xiong, Kai, Yang, Yi, Yang, Yanan, Wang, Zhengbo, Liu, Yun, Duo, Hong, Yuan, Xinya, Xiao, Yao, Xiao, He, Yang, Xueqin |
|---|---|
| Zdroj: | In Neoplasia July 2024 53 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|